Skip to content

Arrowhead Research ARWR Total Non-Current Liabilities

Total Non-Current Liabilities at other companies

Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
$345.61M+191%

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$11.52B+402%
Enterprise value$11.44B+418%
P/S18.5×+14.3×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesNoncurrent.

The official record: Arrowhead Research’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arrowhead Research's total non-current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arrowhead Research's total non-current liabilities?
Arrowhead Research (ARWR) reported total non-current liabilities of $1.37B in Q1 2026.
How has Arrowhead Research's total non-current liabilities changed year-over-year?
Arrowhead Research's total non-current liabilities increased by 105.5% year-over-year, from $668.73M to $1.37B.
What is the long-term trend for Arrowhead Research's total non-current liabilities?
Over 5 years (2020 to 2025), Arrowhead Research's total non-current liabilities has grown at a 102.7% compound annual growth rate (CAGR), from $20.04M to $686.39M.
What does total non-current liabilities mean?
The total amount of all debts and obligations due after more than one year.
How do you interpret total non-current liabilities?
High levels relative to equity indicate higher financial leverage and potential long-term risk.
How does total non-current liabilities compare across companies?
Standard metric for assessing long-term solvency; peers in biotech often have lower long-term debt compared to capital-intensive industries.